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Abstract
Background: CDH3 on 16q22.1 is responsible for two rare autosomal recessive disorders with hypotrichosis and
progressive macular dystrophy: Hypotrichosis with Juvenile Macular Dystrophy and Ectodermal Dysplasia,
Ectrodactyly and Macular Dystrophy. We present a new case of Hypotrichosis with Juvenile Macular Dystrophy.
Case presentation: A Spanish male born in 1998 from non-consanguineous healthy parents with a suspected
diagnosis of Keratosis Follicularis Spinulosa Decalvans and Retinitis Pigmentosa Inversa referred to our Genetics
Department (IIS-Fundación Jiménez Díaz).
Molecular study of ABCA4 was performed, and a heterozygous missense p.Val2050Leu variant in ABCA4 was found.
Clinical revision reclassified this patient as Hypotrichosis with Juvenile Macular Dystrophy. Therefore, further CDH3
sequencing was performed showing a novel maternal missense change p.Val205Met (probably pathogenic by in
silico analysis), and a previously reported paternal frameshift c.830del;p.Gly277Alafs*20, thus supporting the clinical
diagnosis..
Conclusions: This is not only the first Spanish case with this clinical and molecular diagnosis, but a new mutation
has been described in CDH3. Moreover, this work reflects the importance of joint assessment of clinical signs and
evaluation of pedigree for a correct genetic study approach and diagnostic.
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Background
The CDH3 gene, on16q22.1, encodes for P-cadherin,
which is expressed in retina epithelial cells and in hair
follicles, being responsible for adherens junctions (cal-
cium dependent cell-cell adhesion molecule) in these
and other epithelial tissues [1, 2]. Additionally, CDH3 is
thought to be a marker of the epithelial tissues progeni-
tor cells and it has been found to be expressed in human
embryonic stem cells [3, 4].
This gene is responsible for two rare autosomal reces-
sive disorders: Hypotrichosis with Juvenile Macular Dys-
trophy (HJMD, OMIM: 601553) [5–17] and Ectodermal
Dysplasia, Ectrodactyly and Macular Dystrophy (EEM,
OMIM: 225280) [18]. Both disorders characterized by
hypotrichosis and progressive retinal dystrophy.
To date, according to Orphanet (http://www.orpha.net,
date of access 11/05/2016) the frequencies of HJMD and
EEM are unknown and across the world only 50 cases of
HJMD and approximately 15 cases of EEM (only three
with molecular characterization) [8, 19] have been
described.
HJMD has been described as macular degeneration
and short sparse scalp hair from birth with hair loss dur-
ing the first months of life [5]. The retinal phenotype is
nowadays being re-evaluated. It has been suggested that
earlier onset is more likely than the juvenile stated on its
name [7, 20–22], and that there is a wider involvement
of the retina (not only the macula) [7, 20–23]. Thus,
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defining the retinal alteration as a more complex retinal
dystrophy rather than a solely macular dystrophy.
The hair can present different types of abnormalities
being pili-torti one of the most frequent (twisted hair
shafts on the long axis, which are brittle, and break at
varying lengths with many areas appearing bald) [5, 24].
It usually affects the scalp but can also affect eyebrows
and eyelashes (body hair is normal) [5, 24].
Patients with EEM syndrome, additionally exhibit a
wider range of features such as split hand/foot malfor-
mation (SHFM) or ectrodactyly along or not with oligo-
dontia, enamel hypoplasia, and widely spaced teeth [18].
The presence of minimal limb abnormalities has been
described in one HJMD patient [6].
Our aim is to present the first Spanish case with
HJMD due to mutations in the CDH3 gene and the im-
portance of an accurate genetic and clinical diagnosis.
Case presentation
A male born in 1998, from the north east of Spain was
referred to Clinical Genetics with a diagnosis of Kera-
tosis Follicularis Spinulosa Decalvans (OMIM 308800,
probable Siemens Syndrome) and Retinitis Pigmentosa
Inversa. He was referred in 2011 to the Department of
Medical Genetics at the Fundación Jiménez Díaz Univer-
sity Hospital for genetic study. The parents and a nine
year old brother were alive and healthy. Nothing of note
was reported at a family level, and neither consanguinity
nor endogamy existed (Fig. 1. Pedigree).
The Dermatological report stated absence of growing
hair since the 1st year of age, pale skin, sparse scalp hair,
punctiform follicular keratosis on cheeks, forehead, eye-
brows and anterior surface of the arms and posterior
surface of the legs, erythema with follicular hyperkera-
tosis and reduction of hair density on eyebrows.
A skin biopsy had been performed, and was informed
as presenting a reduction in the number of scalp folli-
cles, absence of seborrheic glands and infundibular cyst
with keratin granules. The suspected diagnosis was
Keratosis Follicularis Spinulosa Decalvans (Siemens
syndrome).
The patient had been diagnosed with retinal alteration
at the age of two (no other data was available). Further
ophthalmological examination reports were available for
ages four, ten and twelve (Table 1).
The patient underwent an excision of a pedunculated
colorectal polyp and had been diagnosed with Nodular
Lymphoid Hyperplasia of the gastrointestinal tract at the
age of two.
The patient was first referred to our Department for
genetic testing (reports and sample) in 2011, with a diag-
nosis of two unrelated diagnosis, Siemens Syndrome and
Retinitis Pigmentosa Inversa, for testing of the retinal
dystrophy. Further, he was seen at Clinics at the
Fig. 1 Clinical Genetics’ examination and Pedigree. a-e: Clinical Genetics’ examination: pale and dry skin, hypotrichosis of scalp and face (a-c).
Scalp hair: blond and brittle (impression of pili torti) (A and B). Pigmented lesions in face impressive of keratosis and centro-facial lentigine (B and
C). No limbs anomalies (d and e). Pedigree: Wt = wild type
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Department of Genetics at the age of 14 and 15 (Table 2),
when his diagnosis was re-assessed as likely presenting
HJMD, which accounted for both conditions (both the
retinal dystrophy and the hypotrichosis).
Clinical Genetics examination at the age of 14 and 15
revealed generalised pale and dry skin, hypotrichosis that
was confined to scalp, face (no incipient beard nor
moustache at the age of 16) and arms (Fig. 1 a-e). Scalp
hair was blond and brittle (impression of pili torti)
(Fig. 1a), eyebrows and eyelashes (not shown) appeared
normal; although at a younger age a reduction in their
density had been described. Pigmented lesions could be
observed in face, they were impressive of keratosis and
centro-facial lentigine and to our knowledge they were
probably sun exposure related (Fig. 1b and c). No dental,
hands or feet anomalies were noticed (Fig. 1d and e);
when asked, the patient denied needing special dental
care. No other findings were manifest after complete
clinical examination.
First suspected diagnosis, based on the referral infor-
mation, was ABCA4–related maculopathy + Keratosis
Follicularis Spinulosa Decalvans. However, after clinical
examination and further evaluation of the reports, the
suspected diagnosis was HJMD.
An automated DNA extractor (model BioRobot EZ1;
Qiagen, Hilden, Germany) was used for DNA extraction
from peripheral blood collected in EDTA tubes in ac-
cordance with manufacturer instructions.
For the study of ABCA4 gene the following techniques
were used: a) Genotyping APEX (Arrayed Primer Exten-
sion) for ABCA4 gene (Asper biotech, Tartu, Estonia,
http://www.asperbio.com/asper-ophthalmics/stargardt-
disease-cone-rod-dystrophy-abca4/stargardt-disease-tar-
geted-mutation-analysis); b) Sanger sequencing of all the
coding exons and intronic flanking sequences, and c)
MLPA (Multiplex Ligation-dependent Probe Amplifica-
tion) analysis using a commercial kit (SALSA® MLPA®
P151-P152 ABCA4 probemix, MRC-Holland,
Amsterdam, the Netherland) to study ABCA4 exonic de-
letions or duplications. b) And c) where analyzed by ca-
pillary electrophoresis (Abiprism 3130; Sequencing
Analysis v5.2), performed at our Genetics Department,
Fundación Jiménez Díaz University Hospital, Madrid)
For the study of the CDH3 gene: a Sanger sequencing
of all the coding exons and intronic flanking sequences
of CDH3 was performed at Imegen (Instituto de Medi-
cina Genómica, Valencia, Spain).
For confirmation and segregation of the changes found
in CDH3, Sanger sequencing was performed at our Gen-
etics Department. The brother was not studied as the
majority of international guidelines addressing genetic
carrier testing in children do not recommend it. How-
ever, we did recommend that when he becomes an adult,
a carrier testing (for both ABCA4 and CDH3) is
performed.
First, and based on the initial clinical suspicion of two
different conditions being present in the patient (patient
was referred along with the sample for retinal dystrophy
testing as presenting two unrelated entities), a study of
isolated juvenile macular dystrophy was performed. Only
Table 1 Patient’s ophthalmological examinations since the age of four
Age Visual Acuity and Visual Field (RE/LE) Ophthalmoscopy VEP Electroretinogram
4years–
5years
First symptoms: reduction of VA and central
VF. VA: 0.08/0.1 (5years)




10year NA NA Abnormal RE: scotopic: normal, cones response: lower limit of
normality. LE: moderate decline of all responses
12years VA 0.15/0.15.
VF: Loss of the central 20° and 10° RE and LE




BE Both eyes, LE Left eye, NA Not Available, RE Right eye, VA Visual Acuity, VEP Visual Evoked Potentials, VF Visual Field, Yr Years
Table 2 Timeline
Year (age in years)
2000 -First visit to Dermatology due to absence of hair
growth
-Excision of a pedunculated colorectal polyp: Nodular
Lymphoid Hyperplasia of the gastrointestinal tract
2002 (4) -First visit to Ophthalmolgy: Maculopathy was
suspected
2003 (5) -Maculopathy vs inverse retinitis pigmentosa





2011 (13) -Referral for Genetic testing (bloods and reprots): clinical
suspicion ABCA4 –related maculopathy + Keratosis
Follicularis Spinulosa Decalvans -Genetic tests: APEX
(Arrayed Primer Extension) chip, sequencing and MLPS
(multiplex ligation-dependent probe amplification) for
ABCA4 gene: heterozygous for c.6148G > C,
p.Val2050Leu. No second allele was found
2012 (14) -First visit to Clinical Genetics, diagnosis re-assessment:
Hypotrichosis with Juvenile Macular Dystrophy
2013 (15) -Genetic Tests: CDH3 sequencing: c.830del;
p.Gly277Alafs*20 (paternal) and c.613G > A; p.Val205Met
(maternal)
-2nd visit to Clinical Genetics, confirmed diagnosis:
Hypotrichosis with Juvenile Macular Dystrophy due to
CDH3 mutations
Blanco-Kelly et al. BMC Medical Genetics  (2017) 18:1 Page 3 of 6
a heterozygous missense mutation (c.6148G > C,
p.Val2050Leu; NM_000350 RefSeq) in ABCA4 was
found. After a comprehensive analysis of coding regions
and gene rearrangements a second allele was not found.
Further, and after the re-assessment of the patient on
his appointment at Clinical Genetics, CDH3
(NM_001793.5 RefSeq) sequencing allowed to detect
compound heterozygous variants: a novel maternal mis-
sense change c.613G > A; p.Val205Met, predicted as
probably pathogenic by in silico analysis (dataset
dbnsfp30a implemented in ANNOVAR was used.
(Table 3), and a previously reported paternal frameshift
c.830del; p.Gly277Alafs*20 [7].
Several evidences strongly support that p.Val205Met
in CDH3 is a very likely pathogenic variant and seems to
be responsible for our patient’s clinical findings: a) high
evolutionary conservation of the amino-acid residue that
is located at a calcium-binding site (sites crucial for
function and stability of cadherins [25], Fig. 2a and b), b)
an in silico damaging effect on the protein is predicted
in 10 out of 12 in silico tools, (Table 3), c) its absence in
ExAC database (http://exac.broadinstitute.org/gene/
ENSG00000062038, date of access 04/04/2016), d) the is
change co-segregating with the disease,, and e) a pheno-
type highly suggestive of CDH3.
This way, clinical revision along with directed genetic
study allowed reclassifying this patient as HJMD due to
CDH3 mutation.
Conclusions
We have presented a patient with a phenotype of HJMD.
The fact that no other alterations were observed, apart
from retinal dystrophy and hypotrichosis, allowed us to
discard EEM. Although no radiological examination of
hand or feet was performed, which would completely
rule out EEM, on clinical examination no abnormality
was noted. Mild anomalies of hand and feet have been
noted in EEM patients misdiagnosed with HJMD [6, 19],
we believe that this is not the case in our patient. Mild
changes (as subtle shortening of distal phalanges or mild
toe syndactyly) were not observable on the thorough
clinical examination, performed on our patient.
The presence of two compound heterozygous muta-
tions in the CDH3 gene in our patient, supported our
clinical suspicion.
The ABCA4 gene was studied because it is the most
frequent gene responsible for macular dystrophy in the
young [26] and the retinal phenotype stated in the avail-
able reports were suggestive of macular dystrophy. As
previously mentioned, first suspected diagnosis, based
on the referral information, was ABCA4–related macu-
lopathy + Keratosis Follicularis Spinulosa Decalvans.
Even if our patient presented a mutation on the ABCA4
gene, it was discarded as responsible for the patient’s
maculopathy as no second mutation was found. We can-
not rule out that the p.Val2050Leu mutation in ABCA4
is playing a role in the patient’s ophthalmological pheno-
type. However, there is no known functional interaction
between ABCA4 and CDH3 at a genetic or protein level;
and, the pathogenic effect of the p.Val2050Leu change in
ABCA4 is nowadays discussed (http://www.ncbi.nlm.-
nih.gov/clinvar/?term=%22Retina%20International%22[-
submitter]+AND+%22ABCA4%22[gene], date of access
04/04/2016). Additionally, the prevalence of patients af-
fected by retinal dystrophy carrying an ABCA4 mutation
with another causative gene for their retinal dystrophy is
not rare [27].
As it has previously been noted the main differential
diagnostic of HJMD from an ophthalmological point of
view is not only Stargardt’s disease, which is caused
mainly by ABCA4 mutations [20], but any retinal dys-
trophy phenotype suggestive of CDH3, regardless of the
hair phenotype [22]. However, when patients access a
Clinical Genetics Department they have to be evaluated
as a whole. The presence of two genetic disorders in a
given patient, one being retinal dystrophy may occur
[28]. Nevertheless, in these co-occurrence cases, it is
more likely that the different signs and symptoms are
due to the same genetic cause.
Nowadays, performing an accurate diagnosis is essen-
tial since cell and gene therapy are being evaluated in
retinal dystrophies [29, 30], and phenotypic and genetic
characteristics are to be considered when selecting pa-
tients for future treatments [23].
Besides, the suspected dermatological diagnosis (Sie-
mens Syndrome, OMIM: 305100) is an X-linked trait
Table 3 Functional prediction of p.Val205Met variant on CDH3
gene. Prediction and score from 12 different predictors
Nucleotide variation: NM_001793.5:c.613G > A
Amino-acid variation: p.Val205Met
Mutation type: nonsynonymous SNV
Exon: 6
In silico predictors Prediction (score)
SIFT Deleterious (0)
Polyphen Deleterious (1)
Mutation Taster Deleterious (1)
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and has additional skin changes, not present in our pa-
tient. Therefore, the patient’s pedigree and phenotype
were unlikely to suggest this inheritance model and
diagnosis.
Interestingly, our patient’s retinal alteration was first
noticed when he was two years of age and he was diag-
nosed as presenting Retinitis Pigmentosa Inversa. This
fact supports the idea of an early onset retinal dystrophy
rather than a juvenile onset, and the existence of a major
implication of the retina beyond the macula [7, 20–23].
Despite the fact that the missense change p.Val205Met
in CDH3 has not been reported previously, we have pre-
sented evidence of its pathogenicity. Moreover, a mis-
sense change has been described in the same aminoacid
position (p.Val205Leu) with a minor allele frequency of
2*10−5 in Asian and Latino populations (http://exac.-
broadinstitute.org/gene/ENSG00000062038, date of ac-
cess 04/04/2016).
To date, the CDH3 gene is the only gene known to be
responsible for HJMD.
HJMD is a very rare disease, fact that makes both its
clinical and genetic diagnosis difficult. However, clinical
aspects when taken together should guide us to a clinical
diagnosis and lead to us to the specific genetic test to be
performed.
The presence of two compound heterozygous muta-
tions in this gene in our patient with a phenotype
highly suggestive of HJMD and the absence of add-
itional systemic anomalies led us to the diagnosis of
the first Spanish case, and one of the very few Cauca-
sian cases, of HJMD and to describe a new mutation
in the CDH3 gene.
Moreover, not only we prove that an accurate clinical
genetic diagnosis is of crucial relevance for leading di-
rected genetic studies, but we have widened the number
of both HJMD cases and CDH3 mutations.
Additionally, we also present the importance of differ-
ential diagnosis in retinal dystrophies (syndromic or not)
as prognosis, follow up, chance of treatment and familiar
implications are deeply linked to the responsible gene.
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